Onsdag 28 Oktober | 21:55:56 Europe / Stockholm
Est. tid*
2027-11-23 07:10 Kvartalsrapport 2027-Q3
2027-08-25 07:10 Kvartalsrapport 2027-Q2
2027-05-26 07:10 Kvartalsrapport 2027-Q1
2027-03-16 N/A Årsstämma
2027-02-24 07:05 Bokslutskommuniké 2026
2026-11-26 07:10 Kvartalsrapport 2026-Q3
2026-08-25 - Kvartalsrapport 2026-Q2
2026-05-27 - Kvartalsrapport 2026-Q1
2026-03-26 - X-dag ordinarie utdelning FLUO 0.00 DKK
2026-03-25 - Årsstämma
2026-02-25 - Bokslutskommuniké 2025
2025-11-27 - Kvartalsrapport 2025-Q3
2025-08-28 - Kvartalsrapport 2025-Q2
2025-05-28 - Kvartalsrapport 2025-Q1
2025-03-28 - X-dag ordinarie utdelning FLUO 0.00 DKK
2025-03-27 - Årsstämma
2025-02-27 - Bokslutskommuniké 2024
2024-11-27 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-30 - Kvartalsrapport 2024-Q1
2024-03-21 - X-dag ordinarie utdelning FLUO 0.00 DKK
2024-03-20 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-29 - Kvartalsrapport 2023-Q3
2023-08-30 - Kvartalsrapport 2023-Q2
2023-05-31 - Kvartalsrapport 2023-Q1
2023-03-22 - X-dag ordinarie utdelning FLUO 0.00 DKK
2023-03-21 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-11-24 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-31 - Kvartalsrapport 2022-Q1
2022-05-19 - X-dag ordinarie utdelning FLUO 0.00 DKK
2022-05-18 - Årsstämma
2022-03-30 - Bokslutskommuniké 2021
2021-11-24 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-26 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning FLUO 0.00 DKK
2021-02-26 - Bokslutskommuniké 2020
2021-02-09 - Årsstämma
2020-11-20 - Kvartalsrapport 2020-Q3
2020-08-14 - Kvartalsrapport 2020-Q2
2020-05-27 - Kvartalsrapport 2020-Q1
2020-04-09 - X-dag ordinarie utdelning FLUO 0.00 DKK
2020-04-08 - Årsstämma
2020-02-28 - Bokslutskommuniké 2019
2019-11-29 - Kvartalsrapport 2019-Q3
2019-05-31 - Kvartalsrapport 2019-Q1
LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
FluoGuide är ett danskt bolag verksamt inom medicinteknik. Bolaget affärsfokus återfinns inom forskning och utveckling av behandlingar av olika cancerformer, med störst fokus på utveckling av produkter som vägleder vid kirurgiska ingrepp. Produkterna binder till sig cancercellerna som då lyser upp och är avsedda att användas för att med precision kunna ta bort skadliga tumörer i patientens vävnad.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

FluoGuide intends to carry out a directed share issue of approximately SEK 75 million

2021-05-11 17:36:10
Copenhagen, Denmark, 17:31 CEST, 11 May 2021 – FluoGuide A/S (publ), a developer of surgical precision solutions within oncology (“FluoGuide” or the “Company”) (Nasdaq First North Growth Market: FLUO) hereby announces its intention to carry out a directed share issue of approximately SEK 75 million to Swedish and international institutional investors (the “Directed Share Issue”). The Company has retained Skandinaviska Enskilda Banken AB and ABG Sundal Collier to act as Joint Bookrunners (the “Joint Bookrunners”) in connection with the directed share issue. Sedermera Fondkommission has been retained to act as Co-Manager in connection with the directed share issue.

The subscription price and the total number of new shares in the Directed Share Issue will be determined by way of an accelerated bookbuilding procedure (the “Bookbuilding”). The Company believes that using the flexibility provided by the Directed Share Issue is the most appropriate alternative for the Company at this time, allowing it to raise capital in a timely and cost-effective manner and to diversify the shareholder base. By establishing the subscription price in the Directed Share Issue through an accelerated bookbuilding procedure, it is the assessment of the board of directors that the subscription price will accurately reflect current market conditions and demand.

The Bookbuilding will start immediately following this announcement. Pricing and allocation of the new shares in the Directed Share Issue is expected to take place before beginning of trading on Nasdaq Stockholm at 09:00 CEST on 12 May 2021. The exact timing of closing of the Bookbuilding, pricing and allocation is at the discretion of the Company and the Joint Bookrunners. The Company will announce the outcome of the Directed Share Issue immediately after closing of the Bookbuilding in a subsequent press release.

The net proceeds of the Directed Share Issue are intended to be used for: i) one phase II study with the lead product FG001 in new prevalent indications in 2021, ii) preparation of a phase III study in 2022 iii) preclinical studies on FG002, and iv) general corporate and financial dispositions.

Consummation of the Directed Share Issue is, among other things, subject to a resolution by the board of directors of FluoGuide to issue new shares, pursuant to the authorization given by annual general meeting on 9 February 2021, following closing of the Bookbuilding.

In connection with the Directed Share Issue, the Company and members of the board of directors and management of FluoGuide, has agreed pursuant to a lock-up undertaking, subject to customary exceptions, not to issue or sell additional shares for a period of 90 days following settlement of the Directed Share Issue.
 


This disclosure contains information that Fluoguide is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 11-05-2021 17:36 CET.